Michael Cartwright, MD
Neurology · Winston Salem, NCNPI 1417987827
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,570 of the $8,114 with a category attached, or 68.6%. Novartis Gene Therapies, Inc. (fka Avexis, Inc.) accounts for 67.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $5,228 and has fallen 91.3% since, to $454 in 2025.
Across 70 payments — averaging $115.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$5K
- Genentech USA, Inc.$690
- Biogen$635
- Cadwell Industries, Inc$477
- PTC Therapeutics, Inc.$271
- Novartis$135
- plus $471 from 9 others
Across 22 payments — averaging $10,023 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$207K
- Sarepta Therapeutics, Inc.$14K
What the payments were for
- Consulting fees$6909%
- Speaking & faculty fees$5,57069%
- Food & beverage$1,46618%
- Education$3885%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 6 | $5,435 |
| Genentech USA, Inc. | 1 | $690 |
| Biogen | 9 | $635 |
| Cadwell Industries, Inc | 9 | $477 |
| PTC Therapeutics, Inc. | 31 | $271 |
| Novartis | 2 | $135 |
| Argenx US, Inc. | 1 | $123 |
| NS Pharma, Inc. | 1 | $104 |
| CSL Behring | 2 | $51 |
| Amylyx Pharmaceuticals, Inc. | 1 | $49 |
| Catalyst Pharmaceuticals, Inc. | 2 | $45 |
| AstraZeneca | 2 | $39 |
| Natus Medical Incorporated | 1 | $32 |
| Sarepta Therapeutics, Inc. | 1 | $16 |
| Sanofi | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,114 in reported general payments places this provider in the 75th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvrysdiRisdiplam | 42 | $1,116,849 |
| VyvgartEfgartigimod Alfa-Fcab | 11 | $771,757 |
| SkyclarysOmaveloxolone | 16 | $511,299 |
| Radicava OrsEdaravone | 29 | $407,251 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $313,443 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $261,557 |
| Riluzole | 86 | $10,274 |
| Pyridostigmine Bromide | 25 | $4,431 |
| Gabapentin | 83 | $2,317 |
| Mycophenolate Mofetil | 21 | $1,725 |
| Baclofen | 27 | $918 |
| Pregabalin | 23 | $602 |
| Prednisone | 84 | $548 |
| Mirtazapine | 14 | $489 |
| MethotrexateMethotrexate Sodium | 11 | $455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Evrysdi | $690 | $1,116,84942 claims |
| Argenx US, Inc.Vyvgart | $123 | $771,75711 claims |
| BiogenSkyclarys | $635 | $511,29916 claims |
| CSL BehringPrivigen | $51 | $261,55714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 566 neurology providers in North Carolina.
Other neurology in Winston Salem
- Mustafa SiddiquiWinston Salem$162K
- Rachana Gandhi MehtaWinston Salem$94K
- David HosfordWinston Salem$90K
- Edward HillWinston Salem$50K
- Deepal Shah-ZamoraWinston Salem$42K
- Jill ConwayCharlotte$1M
- Matthew CarraroCharlotte$695K
- Richard SaterGreensboro$682K
- Sara SaccoMatthews$651K
- Megan DonnellyCharlotte$601K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.